We are pleased to announce that Katie Bond has joined the firm as a Partner in the Washington, D.C. Office. Focused on the industries of food and beverages, nutritional supplements, cosmetics and pharmaceuticals, Amin Talati MORE >see all news >
We support clients throughout the entire lifecycle of products aimed at improving the population's health and wellness: food and beverages, nutritional supplements, cosmetics, medical devices and pharmaceuticals.MORE
Drawing heavily on our IP, patent and trademark expertise, we provide our clients with business advice and strategies that enhance product value and head off future litigation.MORE
We are deeply experienced in FDA and FTC disputes, patent and trademark infringement cases, class actions, breach of contract and unfair competition claims. We are renowned in the area of Paragraph IV litigation, where companies challenge brand name patents so that medications can be marketed in generic forms.MORE
We provide counseling both to generic companies seeking to challenge patents and bring drugs to market, and to brand name pharmaceutical companies seeking to strategically patent and protect their brand name products in the long term.MORE
Amin Talati was named to the 2018 U.S. News & World Report and Best Lawyers ® “Best Law Firms” list. Notably, in addition to a national ranking, it was named a top, “Tier 1” law firm for Advertising Law in Chicago. These rankings are based on a “rigorous evaluation process” of over 13,000 firms nationwide. “We are […]
Partner Ryan Kaiser recently weighed in on the shakiness of a proposed class action lawsuit “alleging that Forager Project is deceiving shoppers by failing to disclose on pack that its cold-pressed juices are also high pressure processed”. To read the full article on Food Navigator USA, please click HERE.
Partner Joseph Cwik and Associate Jennifer Adams among others earned a ground breaking win on Oct. 27, 2017 when the International Trade Commission (“ITC”) dismissed a Complaint filed by Amarin Pharma, Inc. See, In the Matter of Certain Synthetically Produced, Predominantly EPA Omega-3 Products in Ethyl Ester or Re-esterified Triglyceride Form (ITC Docket No. 3247). Prior […]